Canada Human Fibrinogen Concentrates Market Size, Share, and COVID-19 Impact Analysis, By Product (Fibryga, RiaSTAP, and Others), By Application (Congenital Fibrinogen Deficiency, Acquired Fibrinogen Deficiency & Surgical Procedures, and Other), End User (Hospitals & ASCs, Specialty Clinics, and Others), and Canada Human Fibrinogen Concentrates Market Insights, Industry Trend, Forecasts to 2035Canada Human Fibrinogen Concentrates Market Size, Share, and COVID-19 Impact Analysis, By Product (Fibryga, RiaSTAP, and Others), By Application (Congenital Fibrinogen Deficiency, Acquired Fibrinogen Deficiency & Surgical Procedures, and Other), End User (Hospitals & ASCs, Specialty Clinics, and Others), and Canada Human Fibrinogen Concentrates Market Insights, Industry Trend, Forecasts to 2035

Canada Human Fibrinogen Concentrates Market Size Insights Forecasts to 2035

• The Canada Human Fibrinogen Concentrates Market Size Was Estimated at USD 7.2 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 7.9% from 2025 to 2035
• The Canada Human Fibrinogen Concentrates Market Size is Expected to Reach USD 16.7 Million by 2035

According to a research report published by Spherical Insights & Consulting, The Canada Human Fibrinogen Concentrates Market Size is Anticipated to Reach USD 16.7 Million by 2035, Growing at a CAGR of 7.9% from 2025 to 2035. The Canada human fibrinogen concentrates market is driven by increasing cases of bleeding disorders, such as congenital fibrinogen deficiency, a growing use in trauma and cardiac surgery for quick blood clotting, improved diagnosis through viscoelastic testing, a shift to virus-safe concentrates instead of cryoprecipitate, and provincial health policies that support better plasma therapies in hospitals

 Market Overview

The Canada Human Fibrinogen Concentrates Market includes the production, distribution, and use of therapies based on fibrinogen produced from human plasma. The concentrates work best for patients who have fibrinogen deficiency, bleeding disorders, and trauma blood loss, and need to undergo major surgical procedures. The strong Canadian healthcare system enables doctors to detect and treat uncommon blood disorders that require immediate medical attention. The market depends on three factors, which include hospital needs, regulatory requirements, and the ability to gather plasma. The medical field has achieved better results for early diagnosis and treatment because doctors now have better understanding of medical conditions. Developments in plasma purification enhance the products efficacy and safety. The healthcare system maintains a high demand for clinical services because of its stable operation.

The Canada Human Fibrinogen Concentrates Market is witnessing key trends that will determine its future development. Therapies derived from plasma are increasingly in the spotlight for their demonstrated efficacy in treating bleeding disorders. The greater number of surgical procedures and trauma cases encourages the demand for fibrinogen concentrates in hospitals. The safety and product availability have improved through the development of new plasma collection and separation technologies. The rising awareness about rare bleeding disorders has led to better diagnosis and treatment outcomes.

The Canadian government is instrumental in supporting the human fibrinogen concentrates market. Organizations like Health Canada ensure that high-quality and safety standards are maintained for products derived from plasma. Public funding for healthcare facilitates access to essential blood therapies across all provinces. The projects conducted by Canadian Blood Services (CBS) enhance domestic plasma collection efforts and lower reliance on imported sources.

Report Coverage

This research report categorizes the market for the Canada Human Fibrinogen Concentrates Market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada human fibrinogen concentrates market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada human fibrinogen concentrates market.

Driving Factors

The Canada Human Fibrinogen Concentrates Market exists because complex surgeries have increased, which require hemostatic agents to handle major blood loss during operations that involve cardiovascular and trauma cases. Regulatory approvals for products, such as octapharmas fibryga for treating acquired fibrinogen deficiency in the surgical setting, are accelerating market growth. The growing elderly population leads to higher demand because older people need surgical procedures, and they experience age-related bleeding disorders. The rising incidence of diagnosed congenital and acquired fibrinogen deficiencies has created a greater demand for immediate medical solutions.

Restraining Factors

The Canada Human Fibrinogen Concentrates Market is challenged by the following factors. The complicated and expensive process of extracting and purifying human plasma, which results in a costly final product. Depends on the supply chain of plasma from donors, which may experience shortages. A long time for plasma-derived human products to be approved because they have to comply with very high safety and quality standards. There may be a lack of awareness of rare bleeding disorders in certain areas, which may cause delays in diagnosis.

Market Segmentation

The Canada human fibrinogen concentrates market share is classified into product, application, and end uses.

• The riastap segment accounted for the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The Canada Human Fibrinogen Concentrates Market is segmented by product into fibryga, riastap, and others. Among these, the riastap segment accounted for the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Given the proven scientific efficacy and approval for use, these products are often used. In the treatment of severe bleeding disorders, hospitals prefer concentrates produced from plasma. Quality is ensured by standardized production methods. Use is facilitated by availability within public healthcare systems.

• The congenital fibrinogen deficiency segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

The Canada Human Fibrinogen Concentrates Market is divided by application into fibrinogen deficit & surgical procedures, congenital fibrinogen deficiency, and others. Among these, the congenital fibrinogen deficiency segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. Each stage of a patient’s life needs therapy, thus creating a constant demand. Acquired fibrinogen deficiency due to trauma and surgery can be a significant contributor. Increased surgical volume leads to increased hospitalization. In emergency and trauma settings, fibrinogen concentrate is a necessity. Improved diagnosis leads to increased treatment rates. This market is expected to grow steadily.

• The hospitals & ASCs segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.  

Based on the end used, the Canada Human Fibrinogen Concentrates Market is segmented into hospitals & ASCS, specialty clinics, and others. Among these, the hospitals & ASCs segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. Each stage of a patient’s life needs therapy, thus creating a constant demand. Acquired fibrinogen deficiency due to trauma and surgery can be a significant contributor. Increased surgical volume leads to increased hospitalization. In emergency and trauma settings, fibrinogen concentrate is a necessity. Improved diagnosis leads to increased treatment rates. This market is expected to grow steadily.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Canada Human Fibrinogen Concentrates Market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• CSL Behring
• Octapharma AG
• Grifols S.A.
• Kedrion Biopharma
• LFB Group
• Biotest AG
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Canada, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Canada Human Fibrinogen Concentrates Market based on the below-mentioned segments:

Canada Human Fibrinogen Concentrates Market, By Product

• Fibryga
• RiaSTAP
• Other

Canada Human Fibrinogen Concentrates Market, By Application

• Congenital Fibrinogen Deficiency
• Acquired Fibrinogen Deficiency & Surgical Procedures
• Other

Canada Human Fibrinogen Concentrates Market, By End Uses  

• Hospitals & ASC
• Specialty Clinics
• Other